Form 4: PharmaCyte Biotech Director Jonathan Schechter Acquires Stock Options

Jonathan Schechter, a director at PharmaCyte Biotech, acquired stock options for 38,009 shares at an exercise price of $2.12 on April 30, 2024.

Summary

• On April 30, 2024, Jonathan Schechter, a director of PharmaCyte Biotech, Inc., acquired stock options for 38,009 shares.
• The exercise price of these options is $2.12.
• The options vest in full on the date of the Issuer's next annual meeting of stockholders, subject to Mr. Schechter's continued service.
• The expiration date for these options is April 30, 2034.
• The report indicates that the filing was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. The late filing due to administrative error is a minor negative.

Negatives

• The filing of this form was late due to an inadvertent administrative error.

Risks

• The vesting of the stock options is contingent upon Mr. Schechter's continued service with the company.

Future Outlook

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter.

Management Comments

• This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director can align the director's interests with those of the shareholders.

Next Steps

• The options will vest upon the date of the Issuer's next annual meeting of stockholders, subject to Mr. Schechter's continued service.

Key Dates

Keywords

PharmaCyte Biotech, Director, Stock Options, Beneficial Ownership, Form 4, Schechter, PMCB